Last updated: July 28, 2025
Introduction
China Patent CN1323663, titled "Medicinal composition of traditional Chinese medicine for treating cancer", exemplifies China's strategic engagement in integrating traditional Chinese medicine (TCM) with modern pharmaceutical innovation. This patent, granted in 2011, embodies the confluence of traditional formulations and contemporary patent practices, with implications spanning from drug development to intellectual property (IP) landscape understanding. This analysis elucidates the scope and claims of CN1323663 and examines its positioning within the patent landscape related to anti-cancer TCM formulations.
Patent Overview
CN1323663 pertains to a medicinal composition combining several plant-derived ingredients reputed for anti-cancer properties. The patent emphasizes a formulation designed to inhibit tumor growth, improve patient immune response, and reduce side effects associated with conventional therapies. The application’s priority date is approximately 2009, with the patent granted in 2011, reflecting China's evolving patent examination standards concerning TCM.
Scope of the Patent
Technical Field
The patent falls within the domain of traditional Chinese medicine formulations with modern pharmaceutical application, specifically targeting anti-cancer therapeutics. It bridges TCM principles and scientific validation, aligning with China's national strategy to modernize traditional medicine.
Intended Use
The patent claims cover the composition’s use in treating various cancers by administering a specific mixture of TCM ingredients. The claims suggest potential applications against tumor proliferation, metastasis, and associated symptoms, emphasizing both therapeutic efficacy and safety.
Product Formulation
The patent delineates a herbal formulation comprising several ingredients, including but not limited to:
- Radix Sophorae Flavescentis (kushen),
- Ganoderma lucidum (lingzhi),
- Panax ginseng,
- Licorice root.
These components are combined in particular ratios, optimized through empirical studies to produce synergistic anti-cancer effects.
Therapeutic Methods
The patent's claims extend to methods of preparation and administration, including dosages, extraction processes, and delivery routes, aiming to standardize treatment protocols for clinical use.
Claims Analysis
The patent presents both independent and dependent claims, with the central theme of defining the composition and its application.
Independent Claims
Claim 1 (Composition Claim):
Defines a herbal medicinal composition comprising specific herbs in designated ratios, intended for use in treating cancer. This claim establishes the core protected formulation.
Claim 2 (Preparation Method):
Specifies a method of preparing the composition involving extraction, mixing, and concentration processes, providing protection over manufacturing techniques.
Claim 3 (Use):
Claims the method of treating cancer using the composition, covering both the formulation and therapeutic application.
Dependent Claims
Dependent claims specify particular herbs or ratios, extraction solvents, or preparation steps, often narrowing the scope but reinforcing patent protection scope.
Scope Evaluation
The scope remains relatively broad in terms of the composition, as it encompasses various combinations within a certain herbal framework. However, the claims' dependent nature constrains the scope, possibly affecting freedom to operate against future innovations. The emphasis on specific ratios and preparation processes narrows protection but also specifies the unique inventive features of this formulation.
Patent Landscape for Chinese Anti-Cancer TCM Patents
Global and Domestic Context
China's patent landscape demonstrates an increasing volume of TCM-related patents, particularly for anti-cancer therapies, driven by supportive policies and growing demand for integrative treatments. The Chinese State Intellectual Property Office (SIPO) has seen a surge in filings, with pharmaceutical companies and research institutions focusing on herbal compositions and extraction methods [1].
Patent Family and Similar Patents
CN1323663 is part of a broader family covering herbal anti-tumor compositions. Similar patents often claim:
- Unique herbal combinations with synergistic effects.
- Specific extraction and preparation protocols.
- Use of the composition for specific cancer types (e.g., lung, stomach, liver).
For instance, patent CN101901322 claims a TCM formulation for lung cancer, emphasizing the importance of robust composition claims. These patents often overlap in ingredients, but varying ratios, preparation methods, and specific therapeutic claims contribute to a complex patent landscape.
Innovative Features and Competitive Edge
The main differentiator for CN1323663 lies in the specific herbal ratios and preparation processes that reportedly enhance efficacy and safety. Advances in extracting active ingredients, standardization techniques, and clinical trial validation contribute to establishing a competitive IP position.
Challenges and Opportunities
Challenges:
- Claim Breadth: Ensuring claims are sufficiently broad to prevent easy workarounds while remaining patentable.
- Prior Art: Navigating a crowded landscape where many similar formulations exist.
- Patentability of Traditional Knowledge: Balancing novelty with the traditional basis of certain ingredients.
Opportunities:
- Combination with Modern Drugs: Bioavailability and synergistic effects open avenues for combination therapies.
- Standardization Protocols: Fostering commercial scale-up within China and export markets.
- Global Patent Filings: Expanding into jurisdictions like the US, Europe, and emerging markets to protect proprietary formulations.
Legal and Commercial Significance
Patent CN1323663 exemplifies China's growing capacity to integrate traditional medicine into commercial pharmaceuticals. It affords exclusive rights covering formulation, preparation, and use, providing a competitive advantage in China’s rapidly expanding TCM market. The patent’s scope influences R&D strategies, identifying potential gaps in prior art and guiding freedom-to-operate assessments.
Conclusion
Patent CN1323663 embodies a strategic TCM approach to anti-cancer therapy, with well-defined formulation and application claims. Its scope balances broad composition coverage with narrower claims on preparation methods. The patent landscape reveals a dynamic environment characterized by incremental innovations, standardization efforts, and increasing international interest. Stakeholders must meticulously analyze patent claims and landscape nuances to navigate IP risks and capitalize on emerging opportunities within China's burgeoning TCM-pharmaceutical sector.
Key Takeaways
- CN1323663's claims focus on specific herbal compositions and preparation methods designed for anticancer efficacy; understanding the scope is vital for R&D and commercialization.
- The patent landscape is increasingly dense with similar formulations; differentiation hinges on ingredient ratios, preparation techniques, and clinical validation.
- Strategic patent drafting—balancing broad claims with specific features—can enhance protection amid crowded prior art.
- Leveraging the patent for global expansion involves acquiring patent freedom and exploring licensing opportunities.
- Clear knowledge of China's TCM patent landscape aids in better IP management and strategic planning.
FAQs
1. How does CN1323663 compare to other traditional Chinese medicine patents in the anti-cancer domain?
It emphasizes a specific herbal formulation with defined ratios and preparation methods, aligning with industry trends toward standardization. Compared to broader patents, CN1323663's claims are more precise, aiming for targeted efficacy and reproducibility.
2. What are the key components protected under this patent?
The key components include Radix Sophorae Flavescentis, Ganoderma lucidum, Panax ginseng, and Licorice root, combined in specific ratios, along with their preparation methods.
3. Can this patent be challenged or designed around?
Yes, patent challenges may arise based on prior art, and competitors might develop alternative herbal formulations with different compositions or preparation methods to design around the patent claims.
4. What is the significance of the preparation method claims?
They protect specific extraction and processing techniques, which can be crucial for ensuring product consistency and patent strength, especially in a field where traditional formulations are often variably prepared.
5. How can foreign pharmaceutical companies utilize this patent information?
They can assess potential licensing opportunities, evaluate infringement risks when developing similar formulations in China, and identify gaps guiding international patent filings for broader protection.
References
[1] Chinese Patent Office data on TCM patents, 2022.
